Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
To verify the role of nab-paclitaxel in neoadjuvant therapy for esophageal squamous cell carcinoma, the investigators designed a prospective, randomized, controlled , multicente phase II trial, to investigate the efficacy and safety of nab-paclitaxel combined with cisplatin as neoadjuvant therapy followed by surgery versus surgery alone for esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
DRUG: Nab-paclitaxel and Cisplatin|PROCEDURE: surgery
OS, Overall survivalï¼ŒFrom date of randomization until death due to any cause, up to 5 years
OS rate, Overall survival rate, 1 year,3years,5years|DFS rate, Disease free survival rate, 1 year,3years,5years|R0 resection rate, R0 resection rate, within 4 weeks following the operation|Down-staging rate, Down-staging rate, within 6 weeks following the last dose of chemotherapy|Rate of Operative Complications, within 4 weeks following the operation|Rate of Adverse Event, Incidence of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, up to 6 weeks after the last dose of chemotherapy
To verify the role of nab-paclitaxel in neoadjuvant therapy for esophageal squamous cell carcinoma, the investigators designed a prospective, randomized, controlled , multicente phase II trial, to investigate the efficacy and safety of nab-paclitaxel combined with cisplatin as neoadjuvant therapy followed by surgery versus surgery alone for esophageal squamous cell carcinoma.